Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, lirag...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Dan, Nair, Ankith, Sigston, Charlie, Ho, Chau, Li, Jia, Yang, Daya, Liao, Xinxue, Chen, Wei, Kuang, Ming, Li, Yanbing, Reid, Christopher, Xiao, Haipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683988/
https://www.ncbi.nlm.nih.gov/pubmed/36474714
http://dx.doi.org/10.1155/2022/6820377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683988/
https://www.ncbi.nlm.nih.gov/pubmed/36474714
http://dx.doi.org/10.1155/2022/6820377

Ejemplares similares